FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
In a major regulatory leadership decision, the U.S. Food and Drug Administration (FDA) has appointed Dr. Richard Pazdur, a long-time oncology expert, as the director of its Center for Drug Evaluation and Research (CDER). Pazdur, who has been with the FDA since 1999 and previously led the Oncology Center of Excellence, is known for his regulatory innovation and deep expertise.
His track record includes expediting cancer drug approvals and championing patient-centric regulation. Colleagues and patient advocacy groups have praised his scientific integrity and compassion-driven leadership.
This appointment comes amid a broader shake-up at the FDA, and brings a steady, experienced hand to one of the agency’s most critical divisions — which oversees both prescription and over-the-counter medicines.
You May Interested In
Glow70/KLOW80 99% China Peptides Warehouse Direct Delivery Lyophilized Powder in Stock
$1.8E+2/UNIT FOB
2026-08-21
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
FDA Revokes Orange B Authorization and Proposes Removing Citrus Red No. 2
-
EFSA’s Updated Food-Additive Application Guidance Takes Effect
-
India Approves ₹30.3 Billion Chemical-Park Scheme to Build Three Mega Industrial Hubs
-
China NMPA Issues Priority Review Pathway for Four Categories of Chemical Active Pharmaceutical Ingredients, Effective August 1, 2026
-
“全球展会数据”功能上线公告 Announcement on the Launch of the “Global Exhibition Data” Function
-
U.S. Imposes 12.5% Additional Tariff! Nutritional Ingredients Including Creatine, Taurine, and Glucosamine Included in New Section 301 Tariff List
-
EFSA Reviews Clodinafop Risk
-
Refrigerant Prices Peak! Domestic Quotas Tighten, U.S. and U.K. Policies Add Fuel to the Fire
-
Medicare’s $50 GLP-1 Door Opens: Weight-Loss Drug Demand Just Got Bigger
-
China’s Hybio Takes Generic Tirzepatide to FDA: Lilly’s GLP-1 Fortress Gets a Warning Shot
Recommend Reading
-
![Sudden Turmoil in Middle East Shipping Routes: Multiple Carriers Announce Emergency Navigation and Surcharge Policies]()
Sudden Turmoil in Middle East Shipping Routes: Multiple Carriers Announce Emergency Navigation and Surcharge Policies
-
![MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies]()
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
![Glyphosate Faces New UK Pressure as EU Trade Alignment Returns to the Debate]()
Glyphosate Faces New UK Pressure as EU Trade Alignment Returns to the Debate
-
![FDA’s Review of BHT and ADA Signals a New Era for Food Additive Compliance]()
FDA’s Review of BHT and ADA Signals a New Era for Food Additive Compliance
-
![Syngenta Bee Pesticide Protest Shows the Pressure Building Around Crop Protection Giants]()
Syngenta Bee Pesticide Protest Shows the Pressure Building Around Crop Protection Giants
-
![Business Society’s View on Gasoline Market Trends on August 13, 2026: Volatile but Rising]()
Business Society’s View on Gasoline Market Trends on August 13, 2026: Volatile but Rising
-
![This week, China's 180CST fuel oil market consolidates at high levels]()
This week, China's 180CST fuel oil market consolidates at high levels
-
![Business Society’s Market Outlook for Petroleum Coke on August 11, 2026: Volatile]()
Business Society’s Market Outlook for Petroleum Coke on August 11, 2026: Volatile
-
![Calcium Propionate Uses: Food Preservation & Industrial Applications]()
Calcium Propionate Uses: Food Preservation & Industrial Applications
-
![Premium Global Chemical Sourcing Requests (28 Feb - 3 Mar, 2026)]()
Premium Global Chemical Sourcing Requests (28 Feb - 3 Mar, 2026)
